{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:49:23Z","timestamp":1773420563365,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.amjms.2015.12.021","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T19:47:19Z","timestamp":1458071239000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease"],"prefix":"10.1016","volume":"351","author":[{"given":"Teresa","family":"Slomka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira O.","family":"Gosmanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syamal K.","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie S.","family":"Oliphant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami N.","family":"Khouzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2015.12.021_bib1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","author":"National Kidney Foundation","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1527-5299.2001.00274.x","article-title":"Pharmacotherapy in congestive heart failure: angiotensin II and thirst: therapeutic considerations","volume":"7","author":"Sica","year":"2001","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.amjms.2015.12.021_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MAJ.0b013e3181cf7d5b","article-title":"Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians","volume":"339","author":"Brener","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjms.2015.12.021_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/sj.ki.5000382","article-title":"The importance of residual renal function in dialysis patients","volume":"69","author":"Wang","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1046\/j.1523-1755.1999.00353.x","article-title":"Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group","volume":"55","author":"Jager","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib6","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.V12102158","article-title":"Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study","volume":"12","author":"Bargman","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2015.12.021_bib7","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0272-6386(01)70006-6","article-title":"K\/DOQI clinical practice guidelines for peritoneal dialysis adequacy, 2000","volume":"37","author":"National Kidney Foundation","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V113556","article-title":"Predictors of loss of residual renal function among new dialysis patients","volume":"11","author":"Moist","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2015.12.021_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5402\/2013\/184527","article-title":"Residual renal function in hemodialysis patients: the role of angiotensin-converting enzyme inhibitor in its preservation","volume":"2013","author":"Xydakis","year":"2013","journal-title":"ISRN Nephrol"},{"key":"10.1016\/j.amjms.2015.12.021_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1744-9987.2012.01087.x","article-title":"Effect of renin-angiotensin system inhibitor on residual glomerular filtration rate in hemodialysis patients","volume":"16","author":"Itoh","year":"2012","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.amjms.2015.12.021_bib11","first-page":"315","article-title":"Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study","volume":"64","author":"Reyes-Marin","year":"2012","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.amjms.2015.12.021_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","article-title":"Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study","volume":"139","author":"Li","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/j.ajkd.2014.05.011","article-title":"Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial","volume":"64","author":"Kjaergaard","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/ki.2015.108","article-title":"Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis","volume":"88","author":"Ha","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1523-1755.2003.00064.x","article-title":"Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000362743","article-title":"Interdialytic weight gain and cardiovascular outcome in incident hemodialysis patients","volume":"39","author":"Lee","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.amjms.2015.12.021_bib18","first-page":"R229","article-title":"Plasma angiotensin II concentrations and experimentally induced thirst","volume":"240","author":"Johnson","year":"1981","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjms.2015.12.021_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/ki.1993.219","article-title":"Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment","volume":"44","author":"Graziani","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1001\/jama.1986.03380050072023","article-title":"Role of angiotensin II in the pathogenesis of hyperdipsia in chronic renal failure","volume":"256","author":"Yamamoto","year":"1986","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.amjms.2015.12.021_bib21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/bmj.296.6629.1089","article-title":"Controlled trial of enalapril in patients with chronic fluid overload undergoing dialysis","volume":"296","author":"Oldenburg","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.amjms.2015.12.021_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0272-6386(12)81059-6","article-title":"Lack of efficacy of angiotensin-converting enzyme inhibitors in reducing interdialytic weight gain","volume":"24","author":"Bastani","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1152\/physrev.00020.2007","article-title":"Physiology and pathophysiology of potassium channels in gastrointestinal epithelia","volume":"88","author":"Heitzmann","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.amjms.2015.12.021_bib24","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/ndt\/gfn321","article-title":"Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis","volume":"23","author":"Fang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000167443","article-title":"Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis","volume":"7","author":"Tzamaloukas","year":"1987","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.amjms.2015.12.021_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0735-6757(99)90131-6","article-title":"ED hemodialysis for treatment of renal failure emergencies","volume":"17","author":"Sacchetti","year":"1999","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1525-1594.2009.00790.x","article-title":"The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function","volume":"33","author":"Garthwaite","year":"2009","journal-title":"Artif Organs"},{"key":"10.1016\/j.amjms.2015.12.021_bib28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/08860220903216147","article-title":"Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients","volume":"31","author":"Lin","year":"2009","journal-title":"Ren Fail"},{"key":"10.1016\/j.amjms.2015.12.021_bib29","first-page":"537","article-title":"Ramipril and risk of hyperkalemia in chronic hemodialysis patients","volume":"35","author":"Krajina-Andricevic","year":"2011","journal-title":"Coll Antropol"},{"key":"10.1016\/j.amjms.2015.12.021_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s11596-012-1035-1","article-title":"Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis","volume":"32","author":"Zhang","year":"2012","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.amjms.2015.12.021_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(86)80120-2","article-title":"Increased secretion of potassium in the rectum of humans with chronic renal failure","volume":"8","author":"Martin","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib32","first-page":"F275","article-title":"Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure","volume":"274","author":"Hatch","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjms.2015.12.021_bib33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0016-5085(94)90184-8","article-title":"Pathophysiology of potassium absorption and secretion by the human intestine","volume":"107","author":"Agarwal","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2015.12.021_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1525-139X.2007.00312.x","article-title":"Management of hyperkalemia in dialysis patients","volume":"20","author":"Putcha","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.amjms.2015.12.021_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/ki.1988.97","article-title":"The anemia of end-stage renal disease: hematopoietic progenitor cell response","volume":"33","author":"Segal","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ndt\/13.5.1206","article-title":"High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients","volume":"13","author":"Albitar","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/ndt\/14.8.1836","article-title":"The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin","volume":"14","author":"Macdougall","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007890-199507270-00004","article-title":"Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism","volume":"60","author":"Danovitch","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.amjms.2015.12.021_bib42","first-page":"1428","article-title":"Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients?","volume":"8","author":"Walter","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib43","first-page":"193","article-title":"Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure","volume":"28","author":"Qureshi","year":"2007","journal-title":"Saudi Med J"},{"key":"10.1016\/j.amjms.2015.12.021_bib44","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1046\/j.1523-1755.2001.00028.x","article-title":"Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin","volume":"60","author":"Hayashi","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1172\/JCI118484","article-title":"Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline","volume":"97","author":"Azizi","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjms.2015.12.021_bib46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2015.12.021_bib47","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1172\/JCI119769","article-title":"Angiotensin II stimulates proliferation of normal early erythroid progenitors","volume":"100","author":"Mrug","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjms.2015.12.021_bib48","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1053\/ajkd.2002.36340","article-title":"ACE inhibitors and survival of hemodialysis patients","volume":"40","author":"Efrati","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib49","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2014a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib50","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinternmed.2012.139","article-title":"Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study","volume":"172","author":"Bajaj","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib51","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ahj.2011.05.004","article-title":"Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis","volume":"162","author":"Chang","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjms.2015.12.021_bib52","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib53","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.2011.228","article-title":"Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients","volume":"80","author":"Chan","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2015.12.021_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0272-6386(97)90490-X","article-title":"Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects","volume":"30","author":"Cannella","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2015.12.021_bib57","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2337\/dc08-0371","article-title":"Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)","volume":"31","author":"Ruggenenti","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjms.2015.12.021_bib58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2002.35680","article-title":"Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors","volume":"40","author":"Paoletti","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2015.12.021_bib59","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","article-title":"Prognostic significance of left ventricular mass change during treatment of hypertension","volume":"292","author":"Devereux","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.amjms.2015.12.021_bib60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib61","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjms.2015.12.021_bib62","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2015.12.021_bib63","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","article-title":"Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis","volume":"5","author":"Tai","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2015.12.021_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e318249d387","article-title":"Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis","volume":"345","author":"Yang","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjms.2015.12.021_bib65","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjms.2015.12.021_bib66","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2015.12.021_bib67","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/eurjhf\/hft082","article-title":"Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan","volume":"15","author":"Tang","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjms.2015.12.021_bib68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11906-006-0087-7","article-title":"Lessons from the African-American Study of Kidney Disease and Hypertension: an update","volume":"8","author":"Toto","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjms.2015.12.021_bib69","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11906-009-0049-y","article-title":"Management of hypertension in hemodialysis patients","volume":"11","author":"Ram","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjms.2015.12.021_bib70","first-page":"1557","article-title":"Hypertension in haemodialysis patients: is it only hypervolaemia?","volume":"12","author":"Luik","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib71","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/ndt\/7.9.917","article-title":"Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values","volume":"7","author":"Kooman","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","article-title":"Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States","volume":"115","author":"Agarwal","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib73","first-page":"277","article-title":"Drug therapy for hypertension in hemodialysis patients","volume":"96","author":"Horl","year":"2005","journal-title":"Minerva Med"},{"key":"10.1016\/j.amjms.2015.12.021_bib74","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2015.12.021_bib75","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.ki.5002745","article-title":"Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension","volume":"73","author":"Davenport","year":"2008","journal-title":"Kidney Int"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T05:06:00Z","timestamp":1655269560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0002962915000774"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2015.12.021","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2015.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}